AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult subjects with HER2 negative„ÄÅadvanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
BIOLOGICAL: Cadonilimab|BIOLOGICAL: Ivonescimab|DRUG: XELOX|DRUG: SOX
Objective Response Rate,ORR, Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1., 6 months
Progression free Survival, Defined as the time between signing the informed consent form to the disease progression (according to RECIST v1.1 criteria) or death due to any cause., 1 year|Overall survival, Defined as the time between signing the informed consent form to death due to various causes., 2 years|Disease Control Rate, Defined as the proportion of patients who achieved complete response (CR), partial response (PR), and stable disease (SD) according to RECIST v1.1., 6 months|Duration of Response, Defined as the time from response(when CR or PR is first diagnosed) to disease progression or death due to any cause., 6 months|Incidence of adverse events, Use NCI-CTCAE version 5.0 for classification and grading., 6 months
The study consists of a dose escalation and expansion phase to determine the recommended Phase 2 dose (RP2D) for AK104 in combination with AK112 and SOX/XELOX, and a dose confirmation phase which will further characterize the treatment of AK104 in combination at the RP2D.